Endocrinology Weekly Update - October 7th 2025

Endocrinology Update: Isturisa dosing model, YAP–T1D link, Mounjaro expansion and more!

From PK–PD modeling confirming twice-daily Isturisa dosing for Cushing’s disease and new evidence connecting osteoporosis with rotator cuff tears to YAP-driven enterovirus replication in type 1 diabetes models, this week’s update spans hormone disorders and metabolic innovation. Highlights include Eli Lilly’s $1B India manufacturing expansion for Mounjaro, the Revvity–Sanofi partnership advancing a 4-plex T1D autoantibody IVD, and data linking hypothyroidism with increased SIBO risk mitigated by levothyroxine. Also featured: Icovamenib’s sustained 52-week HbA1c benefit across type 2 diabetes subgroups and Health Canada’s approval of Zydus’s liothyronine—marking key progress across endocrinology and metabolic care.

In Today’s Newsletter

🧪 Isturisa dose–cortisol modeling supports BID dosing [1] [03 Oct 2025]

https://cushingsdiseasenews.com/news/isturisa-doses-linked-blood-cortisol-levels-cushings-disease/
Context: Report on European Journal of Endocrinology study modeling osilodrostat and cortisol in ACTH-dependent Cushing’s.
Key point: Higher osilodrostat doses linked to greater early cortisol reductions, nadir at ~1 hour, with effectiveness waning by 10–15 hours at low doses.
Implication: May influence prescriber choice and payer reviews pending full data.

🦴 Osteoporosis tied to rotator cuff tears, shared genetics [2] [China • 03 Oct 2025]

https://www.conchovalleyhomepage.com/business/press-releases/ein-presswire/854921321/new-study-links-osteoporosis-to-higher-risk-of-rotator-cuff-tears/
Context: Press release citing Bone Research analysis using UK Biobank and genetic colocalization.
Key point: Osteoporosis associated with increased rotator cuff tear risk, with six shared loci reported, including a signal near PKDCC.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🦠 YAP boosts enterovirus replication in T1D models [3] [06 Oct 2025]

https://bioengineer.org/hippo-effector-yap-enhances-enterovirus-in-diabetes/
Context: Preclinical β-cell and diabetic mouse data; Nature Communications article referenced.
Key point: YAP activation facilitated enterovirus replication; verteporfin reduced replication in models.
Implication: Signals pipeline investment and modality expansion.

🏭 Lilly plans >$1B India manufacturing push for Mounjaro supply [4] [India • 06 Oct 2025]

https://www.msn.com/en-ie/money/companies/eli-lilly-to-boost-manufacturing-and-supply-in-india-with-1bn-investment/ar-AA1NVPX6
Context: Report of new Hyderabad capability and quality center to coordinate contract manufacturing.
Key point: Investment aimed at scaling global medicine supply, including recently launched Mounjaro in India.
Implication: Signals pipeline investment and modality expansion.

🧪 Revvity–Sanofi to advance 4-plex T1D autoantibody IVD [5] [06 Oct 2025]

https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/
Context: Collaboration to validate and seek regulatory clearance globally on Revvity’s GSP instrument.
Key point: Four-plex dried blood spot and venous assay expands from existing three-plex RUO; access to be widened via Revvity’s lab network.
Implication: May expand screening, initiation, and follow-up at scale.

🧫 Hypothyroidism linked to higher SIBO risk, mitigated by LT4 [6] [06 Oct 2025]

https://www.gastroenterologyadvisor.com/news/hypothyroidism-history-linked-to-small-intestinal-bacterial-overgrowth/
Context: Prospective observational cohort and TriNetX analyses; JCEM publication referenced.
Key point: Elevated SIBO risk in hypothyroidism and autoimmune thyroiditis; lower risk observed among levothyroxine users.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💊 Icovamenib shows 52-week HbA1c durability in T2D subgroups [7] [06 Oct 2025]

https://www.investing.com/news/sec-filings/biomea-fusion-reports-52week-results-from-phase-ii-diabetes-trial-93CH-4273690
Context: COVALENT-111 randomized placebo-controlled Phase II; efficacy analysis limited to small 12-week dosing cohorts after prior hold.
Key point: Sustained HbA1c reductions through Week 52 reported in severe insulin-deficient and GLP-1-treated subgroups (n small).
Implication: May influence prescriber choice and payer reviews pending full data.

🇨🇦 Zydus gets Health Canada nod for liothyronine [8] [Canada • 06 Oct 2025]

https://www.cnbctv18.com/market/zydus-lifesciences-share-price-gets-nod-from-health-canada-for-liothyronine-tablets-19704238.htm
Context: Notice of Compliance for 5 mcg and 25 mcg T3 tablets; manufacturing at Ahmedabad SEZ.
Key point: Approval enables Canadian marketing, alongside USFDA approval for deflazacort oral suspension announced separately.
Implication: Introduces competition that may affect pricing and formulary access.

Why it matters

Dose–exposure–response modeling in Cushing’s may sharpen titration strategies for cortisol control [1].
Bone–tendon genetics suggest combined prevention and monitoring pathways in aging populations [2].
Hippo–YAP biology links virology and autoimmunity, pointing to potential host-directed antivirals [3].
Manufacturing investments in India can stabilize supply chains for incretins and other high-demand medicines [4].
Earlier T1D detection could shift care upstream with autoantibody screening at scale [5].

📢 Stay Ahead in Endocrinology Research!

✅ Contact LucidQuest at info@lqventures.com for strategic guidance on endocrinology innovations and clinical research.

FAQ

How quickly does osilodrostat lower cortisol according to the model?

Cortisol reached a nadir about 1 hour after dosing, with effects waning by 10–15 hours at lower doses, supporting BID administration [1].

Which genetic signal was highlighted in the osteoporosis–rotator cuff analysis?

A shared variant near PKDCC was reported among six loci linking the conditions in Bone Research materials cited by the release [2].

Is YAP inhibition ready for clinical use in enteroviral T1D?

No. Findings are preclinical. Verteporfin reduced replication in models, but clinical testing is not reported in the source [3].

What exactly are Revvity and Sanofi developing?

A four-plex IVD detecting T1D-related autoantibodies on Revvity’s GSP platform, with planned submissions in the US, Europe, and other regions [5].

Does levothyroxine prevent SIBO in hypothyroidism?

The observational data associate LT4 use with lower SIBO risk versus untreated cohorts, but causality is not established [6].

How strong are icovamenib’s 52-week data?

They are subgroup signals from a small sample within a Phase II trial after a hold, with sustained HbA1c reductions reported. Full peer-reviewed details are not provided in the summary [7].

Entities / Keywords

Isturisa, osilodrostat, Recordati; Cushing’s disease; ACTH-dependent Cushing’s; Osteoporosis; Rotator cuff tears; PKDCC; UK Biobank; Hippo pathway; YAP; Enterovirus; Type 1 diabetes; Verteporfin; Eli Lilly; Mounjaro, tirzepatide; Hyderabad; Revvity; Sanofi; Autoantibodies; GSP platform; SIBO; Hypothyroidism; Levothyroxine; Biomea Fusion; Icovamenib; COVALENT-111; HbA1c; Zydus Lifesciences; Liothyronine; Health Canada.